Expressions of stem cell marker genes Sox2 and Oct4 in renal cell carcinoma and their clinical significance

李伟,李晓宇,黄建华,王光春,车建平,彭波,许云飞,姚旭东,郑军华
DOI: https://doi.org/10.3781/j.issn.1000-7431.2014.08.010
2014-01-01
Tumor
Abstract:Objective: To examine the expressions of Sox2 [sex-determining region Y protein (SRY)-related high-mobility group box 2] and Oct4 (octamer-binding transcription factor-4), two key transcription genes in stem cells, in patients with renal cell carcinoma (RCC), and to explore their clinical significance. Methods: Real-time fluorescence quantitative-PCR (RFQ-PCR) and immunofluorescence staining method were used to detect the mRNA and protein expressions of Sox2 and Oct4 in tumor tissues and the corresponding adjacent normal tissues from 86 patients with RCC, respectively. Then the relationships of Sox2 and Oct4 protein expressions with the clinicopathological features and prognosis of these patients were evaluated. Results: Both Sox2 (P 0.05). Survival analysis showed that the RCC patients with lower expressions of Oct4 and Sox2 in tumor tissues had better overall survival compared with the RCC patients with higher expressions (P < 0.05). Conclusion: The overexpressions of Sox2 and Oct4 may play an essential role in the oncogenesis and development of RCC. It is suggested that Sox2 and Oct4 may become the potential therapeutic targets for RCC. DOI:10.3781/j.issn.1000-7431.2014.08.010
What problem does this paper attempt to address?